This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mandell, G. L.
Right arrow Articles by Coleman, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mandell, G. L.
Right arrow Articles by Coleman, E. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2561-2563, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Activities of Antimicrobial Agents against Intracellular Pneumococci

Gerald L. Mandell* and Elizabeth J. Coleman

Division of Infectious Diseases, University of Virginia Health Systems, Charlottesville, Virginia 22908

Received 28 December 1999/Returned for modification 30 April 2000/Accepted 12 June 2000

Pneumococci can enter and survive inside human lung alveolar carcinoma cells. We examined the activity of azithromycin, gentamicin, levofloxacin, moxifloxacin, penicillin G, rifampin, telithromycin, and trovafloxacin against pneumococci inside and outside cells. We found that moxifloxacin, trovafloxacin, and telithromycin were the most active, but only telithromycin killed all intracellular organisms.

* Corresponding author. Mailing address: University of Virginia Health Systems, P.O. Box 801341, Division of Infectious Diseases, Charlottesville, VA 22908-1341. Phone: (804) 924-5942. Fax: (804) 982-0002. E-mail: gm{at}virginia.edu.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2561-2563, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Law, C., Amsden, G. W (2004). Single-Dose Azithromycin for Respiratory Tract Infections. The Annals of Pharmacotherapy 38: 433-439 [Abstract] [Full Text]  
  • Ackermann, G., Rodloff, A. C. (2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. J Antimicrob Chemother 51: 497-511 [Abstract] [Full Text]  
  • Paillard, D., Grellet, J., Dubois, V., Saux, M.-C., Quentin, C. (2002). Discrepancy between Uptake and Intracellular Activity of Moxifloxacin in a Staphylococcus aureus-Human THP-1 Monocytic Cell Model. Antimicrob. Agents Chemother. 46: 288-293 [Abstract] [Full Text]  
  • Fuchs, P. C., Barry, A. L., Brown, S. D. (2002). In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antibiotics, including cefotaxime. J Antimicrob Chemother 49: 399-401 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»